Early Amiodarone in Shockable Cardiac Arrest
Part of paid clinical trials in Portland, Oregon.
- Sponsor
- Oregon Health and Science University
- Study ID
- NCT06680869
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Cardiac Arrest
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Amiodarone Hydrochloride Injection — DRUGThe use of a modified treatment protocol by emergency medical services where the initial dose of amiodarone is given after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt. If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study.
- Usual Care Protocol — OTHERThe use of a usual care treatment protocol by emergency medical services where the initial dose of amiodarone is given after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine, for out-of-hospital cardiac arrest due to a shockable rhythm (ventricular fibrillation or ventricular tachycardia) that is persistent or recurs after at least one defibrillation attempt. If an EMS agency is assigned to this arm, no downstream care after the initial dose of amiodarone is dictated by the study.
Study Details
The primary objective of this pilot, pragmatic stepped-wedge cluster randomized trial is to evaluate if a modified cardiac arrest treatment algorithm calling for the administration of the initial amiodarone dose one 2-minute cycle earlier than current guidelines (during the same cycle as the initial dose of epinephrine) improves the time to amiodarone delivery in those with out-of-hospital cardiac arrest due to refractory ventricular fibrillation or ventricular tachycardia compared to usual care.
Key Dates
- Start date
- Jan 1, 2025
- Status verified
- Dec 2025
- Primary completion
- Dec 31, 2027
- Completion
- Jan 31, 2028
Study Design
- Enrollment
- 585 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Early Amiodarone ProtocolAmiodarone administration after the second defibrillator shock, during the same two-minute cycle as the initial dose of epinephrine.
- Active Comparator: Usual Care ProtocolAmiodarone administration after the third defibrillator shock, one two-minute cycle after the initial dose of epinephrine.
Primary Outcome Measure
Time from emergency medical services (EMS) arrival on-scene (or time of arrest if witnessed by EMS) to the administration of the initial dose of amiodarone in minutes [ Time Frame: up to 1 day ]
Central Contacts
- Joshua Lupton, MD, MPH(503) 418-6706
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Oregon Health & Sciences University | Portland | Oregon | 97035 | Joshua Lupton, MD, MPH (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Portland, OR
By research site
Related Studies
- Immunoinflammatory Response in Post Cardiac Arrest Syndrome (PCAS)Recruiting · MaineHealth · Portland, Maine
- Quality of Pediatric Resuscitation in a Multicenter CollaborativeRecruiting · Children's Hospital of Philadelphia · Los Angeles, California
- Neuroprognostication Bias: A Collaboration to Reduce the Impact of Self-fulfilling Prophecy in Cardiac ARrEstRecruiting · Boston Medical Center · San Francisco, California
- RACE-CARS - RAndomized Cluster Evaluation of Cardiac ARrest SystemsEnrolling By Invitation · Duke University · Durham, North Carolina